Integrative Proteomics and Histone PTMomics Study on Anti-TNBC Effect of JIB-04
Journal of the American Society for Mass Spectrometry · 2025-08-06 · 36 (8) · 1609-1620
DOI: 10.1021/jasms.5c00022 ↗At a glance
Journal article in Journal of the American Society for Mass Spectrometry, published online on 2025-07-02. Written by Shengna Tao and 10 co-authors. Institution: Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China. Major MEDLINE topics: Triple Negative Breast Neoplasms, Proteomics, Histones, Antineoplastic Agents. Cited 1 times so far (Crossref); 54 references. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China, Program of Shanghai Academic Research Leader.
Abstract (original language)
The incidence of malignant breast cancer is increasing, and triple-negative breast cancer (TNBC) is particularly challenging due to its poor prognosis and limited response to conventional treatments. Recently, epigenetic inhibitors have emerged as promising therapeutic strategies for TNBC. JIB-04, that targeted histone lysine demethylases (KDMs), was reported to show anticancer activities against TNBC. However, the molecular mechanism underlying the antitumor effect of JIB-04 remains elusive. Herein, we integrated histone PTMomics and quantitative proteomics to comprehensively characterize histone PTM site changes and signaling pathway alterations. Under JIB-04 treatment, a total of 14 significantly altered histone PTM sites were identified, including previously reported sites (H3K9me2, H3K9me3, and H3K36me3) and two newly reported sites (H3K79me2 and H3K9ac). Proteomic analysis quantified 904 differentially expressed proteins, including 495 upregulated and 409 downregulated proteins. Pathway enrichment analysis suggested that JIB-04 significantly affected the DNA damage response. Further biological evidence demonstrated that JIB-04 modulated DNA damage response, cell cycle arrest, and apoptosis. In summary, our study provides new mechanistic insights into the anticancer activity of JIB-04 and offers new options for the treatment of TNBC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
- State Key Laboratory of Cardiology and Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
ORCID profiles: Minjia Tan
Funding
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Program of Shanghai Academic Research Leader
Cite
APA
Tao, S., Guo, J., Zhang, J., Zhang, M., Wang, Z., Zhang, J., Li, M., Liu, B., Yuan, J., Tan, M., & Zhao, W. (2025). Integrative Proteomics and Histone PTMomics Study on Anti-TNBC Effect of JIB-04. Journal of the American Society for Mass Spectrometry, 36(8), 1609-1620. https://doi.org/10.1021/jasms.5c00022
Vancouver
Tao S, Guo J, Zhang J, Zhang M, Wang Z, Zhang J, et al. Integrative Proteomics and Histone PTMomics Study on Anti-TNBC Effect of JIB-04. Journal of the American Society for Mass Spectrometry. 2025;36(8):1609-1620. doi:10.1021/jasms.5c00022
BibTeX
@article{Tao2025,
author = {Tao, Shengna and Guo, Jingli and Zhang, Jingdan and Zhang, Mingya and Wang, Zhe and Zhang, Jun and Li, Mingjun and Liu, Bin and Yuan, Jian and Tan, Minjia and Zhao, Wensi},
title = {Integrative Proteomics and Histone PTMomics Study on Anti-TNBC Effect of JIB-04},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2025},
volume = {36},
number = {8},
pages = {1609--1620},
doi = {10.1021/jasms.5c00022}
}
EUVIMED